Evidence map›Paper›PMID 37179638›Full record

ArticleACS omega2023

Chromatographic Analysis of the

Methanee Hiranyakorn, Shogo Iwamoto, Asako Hoshinoo, Ryo Tsumura, Hiroki Takashima, Masahiro Yasunaga, Shino Manabe

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Current advances in separation chemistry for antibody purification and analysis.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Methanee HiranyakornLaboratory of Functional Molecule Chemistry, Pharmaceutical Department, Hoshi University, Ebara, Shinagawa, Tokyo 142-8501, Japan.
Shogo IwamotoFushimi Pharmaceutical Co. Ltd., Nakatsu, Marugame, Kagawa 763-8605 Japan.
Asako HoshinooFushimi Pharmaceutical Co. Ltd., Nakatsu, Marugame, Kagawa 763-8605 Japan.
Ryo TsumuraDivision of Developmental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa City 277-8577, Japan.
Hiroki TakashimaDivision of Developmental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa City 277-8577, Japan.ORCID https://orcid.org/0000-0001-6487-7344
Masahiro YasunagaDivision of Developmental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Kashiwa City 277-8577, Japan.ORCID https://orcid.org/0000-0003-3356-0197
Shino ManabeLaboratory of Functional Molecule Chemistry, Pharmaceutical Department, Hoshi University, Ebara, Shinagawa, Tokyo 142-8501, Japan.ORCID https://orcid.org/0000-0002-2763-1414
National Cancer Center Hospital East · JPMaruishi Pharmaceutical (Japan) · JPHoshi University · JPTohoku University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37179638
PMCPMC10173337
OpenAlexW4367307244

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.